Publications

This eLearning focuses on H ydrogen safety – a key safety topic for the industrial gases industry.

This eLearning focuses on hydrogen safety – a key safety topic for the industrial gases industry. This part covers the "Introduction to hydrogen"

This eLearning focuses on oxygen safety – a key safety topic for the industrial gases industry. For further information on oxygen safety, see EIGA publications: EIGA Doc 04, Fire Hazards of Oxygen and Oxygen Enriched Atmospheres EIGA Doc 13, Oxygen Pipeline and Piping Systems EIGA Doc 33, Cleaning of Equipment for Oxygen Service

This Training Material is for the EIGA coupling that is an industry standard for connecting transfilling hoses of production plant loading points to mobile equipment. This Training Package is intended for all users of the EIGA coupling including those who train users.

This Training Material explains the safe use of opening, closing and using an integrated cylinder valve on medicinal oxygen gas cylinders.

EIGA does not recommend that the internal components of an ASU coldbox be subjected to periodic inspections.

This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted. Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted. EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.

This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted. Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted. EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.

This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted. Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted. EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.

This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted. Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted. EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.